“Friday’s announcement from the National Institutes of Health (NIH) that they are dramatically reducing funding for indirect costs for research grants is a threat to research that will disrupt critical medical advances. Funding for indirect costs is essential funding because it pays for the infrastructure that is required to make research possible.
This cut will significantly decrease the federal funding that research institutions receive to conduct critical type 1 diabetes (T1D) research. This includes grants funded by the Special Diabetes Program.
The decades of strong Federal support for T1D research have paid immense dividends. Developing cures requires that strong support to continue. This action is a step backward that hurts not only T1D research and the 1.6 million Americans living with T1D but also research for many other diseases. The impacts will be vast and far-reaching.
We are working with legislators and key decision makers to express our deep concerns and ensure they understand the impact of this decision and any actions that undermine or delay reaching cures.”
